⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ORIC News
Oric Pharmaceuticals, Inc. Common Stock
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
globenewswire.com
ORIC
ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
globenewswire.com
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
globenewswire.com
ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
ORIC
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
globenewswire.com
ORIC